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Abstract
Background: The presence of loss-of-heterozygosity (LOH) mutations in cancer cell genomes is commonly
encountered. Moreover, the occurrences of LOHs in tumor suppressor genes play important roles in oncogenesis.
However, because the causative mechanisms underlying LOH mutations in cancer cells yet remain to be elucidated,
enquiry into the nature of these mechanisms based on a comprehensive examination of the characteristics of LOHs
in multiple types of cancers has become a necessity.
Methods: We performed next-generation sequencing on inter-Alu sequences of five different types of solid tumors
and acute myeloid leukemias, employing the AluScan platform which entailed amplification of such sequences
using multiple PCR primers based on the consensus sequences of Alu elements; as well as the whole genome
sequences of a lung-to-liver metastatic cancer and a primary liver cancer. Paired-end sequencing reads were aligned
to the reference human genome to identify major and minor alleles so that the partition of LOH products between
homozygous-major vs. homozygous-minor alleles could be determined at single-base resolution. Strict filtering
conditions were employed to avoid false positives. Measurements of LOH occurrences in copy number variation
(CNV)-neutral regions were obtained through removal of CNV-associated LOHs.
Results: We found: (a) average occurrence of copy-neutral LOHs amounting to 6.9 % of heterologous loci in the
various cancers; (b) the mainly interstitial nature of the LOHs; and (c) preference for formation of homozygous-major
over homozygous-minor, and transitional over transversional, LOHs.
Conclusions: The characteristics of the cancer LOHs, observed in both AluScan and whole genome sequencings,
point to the formation of LOHs through repair of double-strand breaks by interhomolog recombination, or
gene conversion, as the consequence of a defective DNA-damage response, leading to a unified mechanism for
generating the mutations required for oncogenesis as well as the progression of cancer cells.
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Background
As a common feature of cancer cells, LOHs have
been investigated by cytogenetics, fluorescence in situ
hybridization, comparative genomic hybridization (CGH),
array-CGH, and single nucleotide polymorphism (SNP)-
based microarrays [1–4]. With the application of next-
generation sequencing, analysis of LOH in cancer can
further be conducted at the level of single base resolution
[5, 6]. However, owing to the importance of LOHs giving
rise to loss of major alleles and inactivation of tumor
suppressor genes, hitherto investigations of LOHs in
cancers have been focused mainly on LOHs that yield
homozygous-minor genotypes. Yet a comprehensive un-
derstanding of the properties and origins of LOHs in
cancers requires analysis of all types of LOHs in mul-
tiple cancers.
Accordingly, in the present study next-generation se-
quencing was applied to determine at single-base reso-
lution the LOHs in the genomic sequences of various
types of cancers, covering not only sequence regions that
have undergone loss of heterozygosity but also single
nucleotide changes where a heterozygous position has
mutated to a homozygous one. Thirty tumor-control pairs
of six different types of cancers including glioma (glio-
blastoma and astroglioma), acute myeloid leukemia, gas-
tric adenocarcinoma, hepatocellular carcinoma, primary
lung cancer (pulmonary squamous-cell carcinoma, adeno-
carcinoma and neuroendocrinal carcinoma), and lung-to-
brain metastatic adenocarcinoma were analyzed with the
AluScan platform established by our laboratory, based on
the capture of ~8–25 Mb/genome of inter-Alu sequences
by inter-Alu PCR amplification using multiple consen-
sual Alu sequence-based primers for next-generation se-
quencing [7].
The results obtained on both LOH mutations form-
ing homozygous-major genotypes and those forming
homozygous-minor genotypes have yielded a compre-
hensive LOH landscape across different types of can-
cers that identifies the outstanding characteristics of
cancer LOHs: (a) occurrence of massive percentile LOH
mutations of heterozygous residues in the cancer genomes,
far exceeding the percentile gain-of-heterozygosity (GOH)
mutations of homozygous-major residues; (b) cancer LOHs
are mainly interstitial ones indicative of gene conversion
rather than segmental deletion as the major underlying
mechanism for their production; and (c) cancer LOHs dis-
play preferences for the production of homozygous-major
genotypes over homozygous-minor genotypes, and for
transitional over transversional changes. These character-
istics of cancer LOHs, determined using the AluScan plat-
form and also confirmed by the whole-genome sequences
reported for a lung-to-liver metastatic cancer [8] and a
primary liver cancer [9], indicate that cancer LOHs are
generated mainly by repair of double-strand breaks (DSB)
through interhomolog recombination with the homolo-
gous chromosome serving as repair template. The massive
scale of the interhomolog recombinations called for by the
cancer LOHs suggests that a defective DNA-damage re-
sponse, by weakening cell cycle checkpoints in the cancer
cells, allows the entry of DSB-bearing DNA into the S-
phase of the cell cycle, thereby enabling interhomolog
recombination and production of the LOH and tag-
along GOH mutations needed by the cells during their
post-oncogenesis as well as pre-oncogenesis phases.
Methods
DNA samples
Participation in this study was voluntary and informed
consent was obtained from each of the Han Chinese pa-
tients. Institutional Ethics Committees approvals for this
study were granted by Hong Kong University of Science
and Technology, Second Military Medical University of
Shanghai, The First Hospital of Nanjing, Jiangsu Cancer
Hospital, Chinese University of Hong Kong, and Capital
Medical University of Beijing. Of the thirty patients, five
were diagnosed for adenocarcinoma of the stomach; five
for glioma including three with glioblastoma and two
with astroglioma; five for acute myeloid leukemia; five
for primary hepatocellular carcinoma; five for lung can-
cer including two with pulmonary squamous-cell carcin-
oma, two with pulmonary adenocarcinoma and one with
pulmonary neuroendocrinal carcinoma; and five for lung-
to-brain metastatic adenocarcinoma. Detailed medical re-
cords of the patients are given in Additional file 1: Table S2
footnotes.
DNA samples from normal white blood cells and
leukemia cells were prepared using phenol-chloroform
extraction; and DNA samples from normal lung tissue
and solid tumors were prepared using DNAzol® Reagent
from Life Technologies.
Normal white blood cells were employed as controls
for the tumor samples, except for Lung 4 and Lung 5 in
Table 1 where normal lung tissue served as controls. In
the case of leukemias, normal white blood cells were
separated from leukemia cells by Ficoll density gradient
centrifugation. Sequence data on the whole genome
sequences of a lung-to-liver metastatic lung adenocar-
cinoma and its blood cell control [8], and a primary
hepatitis B positive hepatocellular carcinoma and its
normal liver tissue control (case number DD59) [9],
were obtained online from EBI-SRA at www.ebi.ac.uk/
ena/data/view/ERP001071 and NCBI Short Reads Arch-
ive (accession number SRA076160) respectively.
Inter-Alu PCR and next-generation sequencing
Next-generation sequencing technologies have trans-
formed genetics through their ability to produce giga-
bases of sequence information in a single run. However,
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Table 1 Summary of genotype frequencies and mutation rates for cancer samples analyzed by AluScan and by WGSa
Sampleb Sex Totalc
(Mb)









Rmm RGOH-m RMm RLOH RMm->MM RMm->mm
Gastric 1 M 16.08 99.978 0.760 1.393 0.616 0.616 1.146 1.146 22.277 21.964 17.723 4.241 4.179
Gastric 2 M 24.50 99.952 2.105 2.698 0.531 0.531 0.737 0.717 0.544 0.423 0.287 0.136 2.111
Gastric 3 M 24.84 99.961 2.040 1.903 0.221 0.221 0.138 0.138 2.813 2.390 1.523 0.867 1.756
Gastric 4 M 18.22 99.969 1.327 1.798 0.297 0.297 0.414 0.414 2.809 2.565 1.924 0.641 3.000
Gastric 5 M 16.67 99.975 0.593 1.920 0.606 0.606 0.910 0.910 3.062 2.999 2.593 0.406 6.385
Glioma 1 F 18.92 99.964 1.236 2.381 0.169 0.169 0.086 0.086 1.421 1.421 1.043 0.377 2.765
Glioma 2 M 9.84 99.960 1.707 2.310 0.468 0.468 0.298 0.298 13.154 9.239 6.863 2.376 2.889
Glioma 3 M 21.08 99.959 1.973 2.118 3.166 3.071 4.257 3.920 24.009 22.307 16.484 5.823 2.831
Glioma 4 F 8.89 99.956 2.197 2.240 7.294 7.249 0.154 0.154 4.671 4.269 2.963 1.306 2.269
Glioma 5 M 10.49 99.964 1.776 1.866 4.749 4.702 10.574 9.662 26.622 26.162 21.564 4.599 4.689
Leukemia 1 F 15.36 99.960 1.650 2.367 0.091 0.085 0.039 0.039 0.303 0.275 0.248 0.028 9.000
Leukemia 2 F 13.00 99.956 1.824 2.604 0.085 0.085 0.000 0.000 0.296 0.266 0.207 0.059 3.500
Leukemia 3 M 21.91 99.954 1.799 2.777 0.059 0.059 0.101 0.101 0.427 0.329 0.279 0.049 5.667
Leukemia 4 F 17.75 99.975 0.712 1.773 0.118 0.118 0.238 0.238 1.208 1.017 0.890 0.127 7.000
Leukemia 5 M 20.98 99.975 0.847 1.689 0.243 0.243 0.675 0.675 1.383 1.185 1.016 0.169 6.000
Liver 1 F 10.85 99.980 0.780 1.237 3.881 3.844 10.520 10.284 27.103 26.731 23.083 3.649 6.327
Liver 2 M 17.73 99.962 1.310 2.511 0.717 0.717 1.421 1.291 13.814 12.736 11.927 0.809 14.750
Liver 3 M 12.04 99.955 1.926 2.574 0.590 0.590 0.862 0.862 6.387 5.226 4.323 0.903 4.786
Liver 4 M 7.93 99.965 1.359 2.122 0.605 0.593 1.763 1.391 16.162 16.102 13.131 2.971 4.420
Liver 5 M 11.08 99.957 1.984 2.274 0.352 0.352 0.227 0.227 7.302 6.587 5.357 1.230 4.355
Lung 1 M 11.94 99.952 1.956 2.821 0.260 0.260 0.899 0.899 6.980 6.920 5.495 1.426 3.854
Lung 2 M 12.96 99.956 2.400 1.963 2.454 2.454 1.479 1.318 11.635 11.439 10.653 0.786 13.553
Lung 3 F 14.23 99.964 1.368 2.207 1.680 1.673 3.236 3.236 7.291 6.495 5.858 0.637 9.200
Lung 4 M 12.49 99.965 1.286 2.234 2.811 2.811 6.476 6.413 5.661 5.410 5.016 0.394 12.727
Lung 5 F 14.46 99.950 2.057 2.896 11.609 10.633 20.134 15.261 49.690 48.161 37.751 10.411 3.626
Lung-Brain 1 M 21.69 99.934 2.688 3.884 0.807 0.807 0.583 0.566 2.125 1.840 1.425 0.416 3.429
Lung-Brain 2 M 21.68 99.943 2.432 3.208 0.858 0.844 0.512 0.493 7.346 6.627 4.572 2.056 2.224
Lung-Brain 3 F 17.04 99.948 1.894 3.302 0.564 0.564 1.209 1.178 1.707 1.120 1.013 0.107 9.500
Lung-Brain 4 M 22.79 99.948 1.886 3.292 0.931 0.917 1.024 1.024 5.052 4.679 3.332 1.346 2.475































































































































































































































































































aSee Additional file 3: Table S1 and Additional file 1: Table S2 for data on individual cancer samples
b‘Sample’ refers in rows 1–38 (not counting row of headings) to 30 tumor-control pairs analyzed by AluScan as described in Methods; refers in row 39 to the lung-to-liver metastatic cancer analyzed by Ju et al. [8]
using WGS; and refers in row 40 to the primary liver cancer analyzed by Ouyang et al. [9] using WGS
cOnly nucleotide positions that were captured in both the tumor and the control samples for AluScan sequencing were analyzed and counted
dMutation rates (R) were given in each instance by the ratio [100 % × (number of mutated residues) / (total number of residues analyzed)]. RGOH-M refers to the % of MM residues, and RGOH-m the % of mm residues,
that underwent a GOH mutation. RMm refers to the % of Mm residues that underwent a mutation. RLOH refers to the % of Mm residues that underwent an LOH mutation. The rates of LOHs leading to the production of
MM residues and mm residues are given by RMm->MM and RMm->mm respectively
eThe ratio between the MM residues and mm residues produced from Mm residues by LOH is expressed by MM/mm
fThe average of the individual values for 5 leukemia samples ± SD
gAll Av. values estimated without removal of CNV-associated LOHs and GOHs are shown without parentheses; all Av. values estimated after removal of CNV-associated LOHs and GOHs are shown inside parentheses
hAggregate Av. for Total (Mb) represents 0.2 × total Mb analyzed in the 5 leukemia samples. Aggregate Av. values for the other columns are obtained directly from dividing by 5 the total figures for the 5 leukemia
samples pooled together
i, jSample Av. and Aggregate Av. values are defined as in f and h, but pertain to the 25 solid tumors
k, lSample Av. and Aggregate Av. values are defined as in f and h, but pertain to the 5 glioma tumors














next-generation sequencing of a subset of the genome
captured by inter-Alu PCR with an amplicon range
vastly enhanced by the use of both ‘head type’ and ‘tail
type’ Alu consensus sequence-based PCR primers of op-
posing orientations could substantially reduce the amount
of sample DNA required as well as data analysis [7]. Such
sets of next-generation sequenced inter-Alu PCR ampli-
cons, or AluScans, were employed in this study to provide
an expedited scan of the mutations in exons, introns and
non-coding regions. For this purpose, a 25-μl PCR reaction
mixture contained 2 μl Bioline 10× NH4 buffer (160 mM
ammonium sulfate, 670 mM Tris–HCl, pH 8.8, 0.1 %
stabilizer; www.bioline.com), 3 mM MgCl2, 0.15 mM
dNTP mix, 1 unit Taq polymerase, 0.1 μg DNA sample,
and 0.075 μM each of the four following Alu-based PCR
primers: AluY278T18 (5′-GAGCGAGACTCCGTCTC
A-3′); AluY66H21 (5′-TGGTCTCGATCTCCTGACCT
C-3′); R12A/267 (5′-AGCGAGACTCCG-3′) and L12
A/8 (5′-TGAGCCACCGCG-3′). DNA denaturation was
carried out at 95 °C for 5 min, followed by 30 cycles each
of 30 s at 95 °C, 30 s at 50 °C, and 5 min at 72 °C, and fi-
nally another 7 min at 72 °C. Amplicons were purified
with ethanol precipitation, sequenced on the Illumina-
Solexa platform at Beijing Genomics Institute (Shenzhen,
China) and mapped to the reference human genome
hg19 [10].
AluScan sequencing data mapping and variant analysis
Paired-end sequencing reads were aligned to the
GRCh37.p2 (Feb 2009) reference human genome using
BWA (Burrows-Wheeler Aligner, version 0.6.1) with de-
fault settings [11]. After BAM format-transfer and sort-
ing by SAMtools (Sequence Alignment/Map, version
0.1.18) [12], the reads were further recalibrated and lo-
cally realigned using GATK (Genome Analysis Tool-Kit,
version Lite-2.1-8-gbb7f038) [13] according to the stand-
ard framework [14].
The module ‘UnifiedGenotyper’ in GATK was employed
to perform genotyping, and LOH and GOH callings for
each sample were conducted with default settings. An
LOH was defined as the conversion of a locus from het-
erozygosity in control to homozygosity in tumor, whereas
a GOH was defined as the conversion of a locus from
homozygosity in control to heterozygosity in tumor. Re-
gions of read depths < 8 in either the tumor sample or its
paired control would not be analyzed further. For homo-
zygous reference loci, allele frequency must be 100 %. For
homozygous non-reference loci, non-reference allele fre-
quency must be 100 % with QD ≥ 20. For heterozygous
loci, the non-reference allele must be ≥ 35 % and ≤ 65 %
with Quality by Depth (QD) ≥ 4. Based on these condi-
tions, with a ≥ 8 read depth, recognition of any site on the
control sequence as a heterozygous site required a mini-
mum of three reads bearing the non-reference allele. Since
LOH would be called at this site on the tumor sequence
only when the homozygous genotype was observed to be
100 %, an LOH event would be scored only if all these
three non-reference allele reads in the control were no
longer observed. Strand bias filter was employed to ensure
SB values < −0.01 for both heterozygous loci and homo-
zygous non-reference loci. See Additional file 2:
Methods for more details on methods.
CNV Analysis
A variety of algorithms have been designed for CNV call-
ing from whole genome sequencing (WGS) or exome se-
quencing data. However, the special features of AluScan
data rendered difficult the calling of CNV using the call-
ing algorithms designed for WGS or exome sequencing.
Accordingly, the AluScanCNV method developed by us
to call CNVs from AluScan and other types of sequence
data, based on Geary-Hinkley transformation of read-
depth ratios between either paired test-control samples
or between test samples and a reference template con-
structed from reference samples [15], was employed in
the present study for the identification of CN-gains and
CN-losses.
Genic locations of mutations
The possible genic locations of the called LOH and GOH
loci were identified through comparison with the Ensembl
gene list from the UCSC database (http://genome.ucsc.edu/
cgi-bin/hgTables), the TSGene database (Tumor Suppressor
Gene: http://bioinfo.mc.vanderbilt.edu/TSGene/), and
the NCG4.0 database (Network of Cancer Genes: http://
ncg.kcl.ac.uk/).
Variant analysis of whole genome sequencing data
Raw whole genome sequencing data for a lung-to-liver
metastatic cancer from a lung adenocarcinoma [8], and
a hepatitis B positive hepatocellular carcinoma [9] were
aligned to the GRCh37.p2 (Feb 2009) reference human
genome by using BWA and GATK to extract all the
overlapping sites between blood cell control and tumor
tissue in the case of the lung-to-liver metastatic cancer,
and between normal liver tissue control and tumor tis-
sue in the case of the primary liver cancer. Genotyping
and variant callings were performed for each of these
two DNA samples with the ‘UnifiedGenotyper’ module
in GATK with default settings as described for the AluS-
can samples. Regions of read depths <15 were first
filtered out. Further filtration was achieved using the fol-
lowing criteria: for the homozygous reference loci, allele
frequency must be 100 % and Quality by Depth (QD) ≥ 1;
for heterozygous loci, non-reference allele frequency must
be ≥ 25 % and ≤ 75 % with QD ≥ 4; for homozygous non-
reference loci, non-reference allele frequency must be
100 % with QD ≥20. Phred-scaled p-value using Fisher’s
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exact test to detect strand bias (FS) was employed to en-
sure FS value ≤ 12 for both heterozygous loci and homozy-
gous non-reference loci. The percentile rate of LOH (or
GOH) was estimated by dividing the number of LOHs (or
GOHs) by the number of total Mm sites (or MM or mm
sites) that had passed through the filtration steps de-
scribed above, and multiplying by 100 %.
Results
High rate of LOH occurrence
The genome-wide single base-resolution LOHs detected
in thirty primary and secondary cancers using the AluS-
can platform are summarized in Table 1 and Additional
file 3: Table S1. In these tables, any allele at a residue in
the genome that corresponded to the allele represented
in the reference human genome hg19 was regarded as
M, viz. the reference or major allele; on the other hand,
any allele that differed from the allele on hg19 was
regarded as m, viz. the minor allele. On this basis, the
results in the tables showed that the heterozygous Mm
residues in the genomes of gastric cancers, gliomas, leu-
kemias, liver cancers and primary and secondary lung
cancers all displayed exceptionally high mutation rates
leading to an all-sample RMm equal to 9.15 % of all Mm
residues analyzed, with a great majority of the mutations
giving rise to LOH to yield an RLOH of 8.59 %. In con-
trast, RGOH-M for gain-of-heterozygosity was merely
1.54 × 10−3 % of all MM residues analyzed.
Accordingly, based on the all-sample averages, the
RLOH/RGOH-M ratio for the thirty cancers was 8.59 % /
1.54 × 10−3 % = 5.58 × 103. Because the number of ana-
lyzed residues (viz. base pairs that were mapped in both
the paired cancer and control samples) varied with the
cancer-control pair, aggregate average RLOH was also
estimated directly as the ratio [all LOHs detected] / [all
Mm residues analyzed] in the thirty cancer-control pairs,
and aggregate average RGOH-M as the ratio [all GOH
mutations of MM residues detected] / [all MM residues
analyzed]: thereby the aggregate RLOH/RGOH-M ratio for
the 30 cancers was 6.91 % / 1.30 × 10−3 % = 5.32 × 103.
Thus, by either route, RLOH was more than 5000-fold
greater than RGOH-M. Given the far greater number of
MM residues than Mm residues in genomic sequences,
but far smaller RGOH-M than RLOH values, the total num-
ber of GOH-M mutations in the 30 cancers were of the
same order of magnitude as the total number of LOH mu-
tations (6360 and 8315 respectively) (Additional file 4:
Table S3.31). The vastly unequal rates of LOH and GOH
occurrences also rendered unlikely that the massive num-
bers of LOHs arose from technical errors, which would
have produced LOHs and GOHs randomly at comparable
rates. In fact, based on the use of high density whole
genome SNP arrays, occurrence of copy number-neutral
LOHs was also found to be frequent in gastrointestinal
stromal tumors where contamination of tumor samples
with normal cells was generally low, leading to the sugges-
tion that the frequency of copy number-neutral LOHs
might tend to be underestimated in solid tumors on ac-
count of the low percentages of tumor cells in the samples
[4]. In the present study, as indicated in Methods, all MM
or mm genotypes arising from Mm genotypes must be
100 % for them to be called as LOHs in order to minimize
or obviate the effects of varied percentages of tumor cells
in a tumor sample.
Chromosomal distribution of LOH
The LOHs detected in the thirty cancers analyzed by
AluScan sequencing (Table 1) were mostly distributed
over interstitial sites along the lengths of different chro-
mosomes without extraordinary clustering at the ends of
chromosomes (Figs. 1 and 2). This fundamentally inter-
stitial character of cancer LOHs was readily discerned in
the leukemias (e.g. Fig. 1c) where the majority of the chro-
mosomes displayed sparse, isolated LOH occurrences. It
was equally evident in chromosomal regions with a high
density of LOHs, e.g. chr 19, chr 17, chr 1p and chr 22q in
Fig. 2a, where dense LOHs were closely interspersed with
dense GOHs, indicating that the dense LOHs could not
be derived from long stretches of CN-losses which would
be incompatible with the co-occurrence of dense GOHs
within the same stretches.
Detection of CNV revealed some CNV-dense seg-
ments, e.g. CN-losses in chr 1p, chr 9p and chr 9q of
Glioma 1 which coincided with frequently observed CN-
losses in gliomas [16–18], and CN-gains in chr 1q of
both Glioma 1 and Lung-Brain 4 as well as chr 19p of
Glioma 4 (Fig. 1b, Additional file 5: Table S6; Additional
file 6: Figure S1), but most of the LOHs observed in
the cancers apart from the gliomas were copy-neutral
ones unassociated with either CN-losses or CN-gains
(Additional file 7: Table S4). Even for the glioma samples,
the aggregate average RGOH-M and RLOH were only chan-
ged from 2.69 × 10−3 to 2.45 × 10−3 % and from 12.29 to
12.79 % respectively after subtraction of CNV-associated
GOHs and LOHs (Table 1). Locations of common and
rare fragile sites [19] overlapped some LOH-dense regions
such as those in chr 1p, chr 11q, chr 12q, chr 19p, chr19q,
and chr 22q, but not all LOH-dense regions (Fig. 2a).
In the lung-to-liver metastatic cancer and primary liver
cancer analyzed by WGS sequencing, the LOHs detected
were similarly found to be mainly interstitial along the
lengths of chromosomes rather than concentrated near
the ends of chromosomes (Fig. 2b, c). The GOHs were
also thickly interspersed with the LOHs along various
chromosomes, again ruling out extended segments of CN-
losses as a major cause of the LOHs (Additional file 8:
Table S5). While the AluScan results (Fig. 2a) showed
some of the chromosomes such as chr 19, chr 17, and chr
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22q to be particularly enriched with LOHs and GOHs, the
LOHs and GOHs revealed by WGS were more uniformly
distributed among different autosomal chromosomes,
which is in agreement with the elevated density of Alu ele-
ments in chr 19 and chr 17 and therefore enhanced se-
quence capture from these chromosomes by AluScan
(Additional file 4: Table S3.34). Earlier we also found sin-
gle nucleotide variations to be elevated in the vicinity of
Alu elements [20].
Notably, the RLOH/RGOH-M ratio was ~640-3200 for
the two sets of whole genome sequencing (WGS) data
obtained by Ju et al. [8] and Ouyang et al. [9] (bottom
two lines respectively, Table 1), compared to ~5300 for
the all sample AluScan-based aggregate results. There-
fore these two sequencing platforms were in agreement
regarding the far greater percentile LOH mutations in
cancer genomes compared to GOH mutations.
Preferences for reference alleles and transitional changes
in cancer LOHs
In an LOH event, a heterozygous Mm residue with two
different allelic bases on homologous chromosomes is
mutated to a homozygous MM residue or a homozygous
mm residue. In this regard, any residue in a human gen-
ome can be classified into the A-, G-, T- or C-family, de-
pending on whether the reference allele at the same
nucleotide position in the hg19 reference was an A, G, T
or C. A preference for the reference (or M) allele repre-
sented by dark red or blue columns over the non-
reference (or m) allele represented by light red or blue
columns was observed for the LOHs arising from all 12
different types of Mm residues (Fig. 3a). Furthermore,
transitional LOHs that produced the MM genotype
(dark red columns), converting Ag to AA, Ga to GG, Tc
to TT and Ct to CC, were far more prominent than
Fig. 1 Chromosomal distributions of mutations in individual AluScan samples. LOHs (red bars) and GOHs (blue bars) detected from the AluScans
of each tumor-control pair are plotted above the cytobands, and CN-gains (green bars) and CN-losses (purple bars) plotted below the cytobands,
for six representative cancer samples. a Gastric 1, b Glioma 1, c Leukemia 1, d Liver 1, e Lung 1, and f Lung-Brain 1. Similar distributions for another
twenty-four cancers are shown in Additional file 6: Figure S1. Complete listings of LOHs, GOHs and CNV sites in all thirty cancer samples, and
comparison of the detected CNVs with those in the TCGA database [60] are given in Additional files 7: Table S4, Additional file 8: Table S5,
Additional file 5: Table S6, respectively. Clinical information on each patient is indicated in the footnotes to Additional file 1: Table S2
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transversional LOHs that produced the MM genotype
(dark blue columns), converting At to AA, Ac to AA, Gt
to GG, etc. Since the M-allele preference applied to
LOHs arising from Mm residues belonging to all of the
A-, G-, T- and C-families, it was distinct from GC-biased
gene conversions [21].
M-allele preference was also displayed by the LOHs in
the secondary lung-to-liver metastatic cancer [8] and the
primary liver cancer [9] analyzed using WGS. Amongst
the LOHs giving rise to MM genotypes in Fig. 3b, there
was greater prominence of transitional LOHs than trans-
versional LOHs as well. In Fig. 3c, the Ag-AA, Tc-TT
and Ct-CC transitions remained prominent, but two of
the transversions, viz. Ac-AA and Tg-TT, were likewise
pronounced; whether this was related to the use of nor-
mal liver tissue as control in this instance remains to be
determined. Thus the AluScan and WGS results were in
accord with respect to M-allele preference, and both
Fig. 2 Chromosomal distributions of total mutations. a All LOHs and GOHs detected from AluScans of thirty cancer samples. b LOHs and GOHs
detected from the whole genome sequences of a lung-to-liver metastatic cancer and its white blood cell control determined by Ju et al. [8]. c
LOHs and GOHs detected from the whole genome sequences of a primary liver cancer and its normal liver tissue control determined by Ouyang
et al. [9]. LOHs are shown as red vertical bars above cytobands, and GOHs as blue vertical bars below cytobands. The locations of common
and rare fragile sites [19] are represented by horizontal green lines above, and horizontal orange lines below, the cytobands respectively. The
chromosomal locations of all LOH and GOH sites are listed in Additional files 8: Table S5 and Additional files 5: Table S6
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favored a prominence of transitional LOHs. A greater
prominence of transitional relative to transversional
LOHs is difficult to explain in terms of technical biases
but consistent with the known higher transitional muta-
tion rates relative to transversional mutation rates.
Occurrence of LOH and GOH in cancer related genes
A large number of tumor suppressor genes and other can-
cer related genes in the AluScan sequence reads of the 30
cancer genomes, identified based on the TSGene and
NCG4.0 databases, underwent LOH and GOH mutations
(Additional file 9: Table S7). Table 2 shows the genes that
displayed such mutations in multiple cancer samples,
which would represent genes with a high likelihood
to participate in the oncogenic pathways of the vari-
ous cancers.
To facilitate delineation of the genetic basis of human
diseases, the bioinformatics tool CIPHER [22] has been
developed to predict and prioritize disease genes based
on the concordance between human protein network and
disease phenotype network. Figure 4a shows an inter-
action network module associated with the solid tumor
group, where the high-risk genes identified for this group
by CIPHER based on database STRING [23] (Additional
Fig. 3 Preferences for reference alleles and transitional changes displayed by LOH mutations. The frequencies for the reference (i.e. major) allele
versus the minor allele amongst the LOH products are shown by twin columns for transitional LOHs (red) and transversional LOHs (blue). The
dark red and blue columns represent Mm-to-MM conversions (e.g. Ag-to-AA. indicated as Ag-AA), and the light red and blue columns represent
Mm-to-mm conversions (e.g. Ag-to-gg indicated as Ag-gg). a Total preference profile of the thirty cancers in Table 1 analyzed by AluScan
(obtained from the preference profiles of individual cancers given in Additional file 12: Figure S2). b Preference profile of the lung-to-liver metastatic
cancer analyzed by WGS [8]. c Preference profile of the primary liver cancer analyzed by WGS [9]
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Table 2 Genes with LOH or GOH mutations in multiple cancer samplesa
A. Genes in TSGene database with LOH occurrence in three or more cancer samplesb
Chrc Gene Description Samples with LOH sitese
6 AKAP12d A kinase (PRKA) anchor protein 12 Gastric1, Gastric3, Liver1
6 PARK2 Parkin RBR E3 ubiquitin protein ligase Glioma3, Glioma5, Lung5
7 FBXL13 F-box and leucine-rich repeat protein 13 Glioma3, Liver1, Lung5
7 CUX1d Cut-like homeobox 1 Glioma5, Liver4, Lung5, Lung-Brain3
8 CSMD1d CUB and Sushi multiple domains 1 Gastric1, Glioma2 (2), Glioma3 (2), Liver1, Liver3, Liver5,
Lung1, Lung5, Lung-Brain2 (1 + 1)
8 MFHAS1 Malignant fibrous histiocytoma amplified sequence 1 Gastric1, Liver4, Liver5
9 PPP2R4 Protein phosphatase 2A activator, regulatory subunit 4 Glioma1, Lung3, Lung5
9 PTPRDd Protein tyrosine phosphatase, receptor type, D Glioma1, Glioma3, Leukemia5, Liver1, Lung5 (3),
Lung-Brain2
9 ROR2 Receptor tyrosine kinase-like orphan receptor 2 Gastric1 (3), Glioma3, Lung2
11 NUP98d Nucleoporin 98 kDa Gastric3, Glioma3, Liver2, Lung-Brain1 (3)
12 CHFR Checkpoint with forkhead and ring finger domains, E3
ubiquitin protein ligase
Glioma3, Liver2, Lung-Brain4
14 EGLN3 Egl-9 family hypoxia-inducible factor 3 Lung5 (1 + 1), Lung-Brain4, Lung-Brain5
16 DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3 Liver4, Lung1, Lung5
16 AXIN1d Axin 1 Glioma2, Liver1, Lung5
19 GLTSCR1d Glioma tumor suppressor candidate region gene 1 Glioma5, Lung5, Lung-Brain4
22 PRR5 Proline rich 5 (renal) Glioma3, Liver3, Lung5
B. Additional genes present in NCG4.0 database with LOH occurrence in three or more cancer samplesb
Chrc Gene Description Samples with LOH sitese
1 SMG5 SMG5 Nonsense Mediated MRNA Decay Factor Liver2, Lung1, Lung5 (3), Lung-Brain2, Lung-Brain4
1 KAZN Kazrin, Periplakin Interacting Protein Gastric3, Liver1, Lung5, Lung-Brain2
2 CTNNA2 Catenin (Cadherin-Associated Protein), Alpha 2 Lung1, Lung3, Lung5 (2 + 2)
2 DPP10 Dipeptidyl-Peptidase 10 (Non-Functional) Gastric1, Glioma3, Glioma5
3 ERC2 ELKS/RAB6-Interacting/CAST Family Member 2 Gastric3, Glioma3, Lung2
4 ELOVL6 ELOVL Fatty Acid Elongase 6 Glioma3, Glioma4, Lung-Brain2
4 FSTL5 Follistatin-Like 5 Glioma2, Lung5, Lung-Brain2
5 AFF4 AF4/FMR2 Family, Member 4 Gastric1, Glioma3, Lung5 (2)
5 DMGDH Dimethylglycine Dehydrogenase Gastric1, Liver5 (2), Lung2, Lung-Brain4
7 HIP1 Huntingtin Interacting Protein 1 Gastric1, Glioma5, Liver1, Liver4, Lung2, Lung5,
Lung-Brain2
7 CARD11 Caspase Recruitment Domain Family, Member 11 Glioma2, Glioma5, Lung-Brain5
8 RIMS2 regulating synaptic membrane exocytosis 2 Glioma3 (1 + 1), Lung5, Liver5
9 FNBP1 Formin Binding Protein 1 Gastric5, Glioma5, Liver2 (2)
10 SORCS1 Sortilin-Related VPS10 Domain Containing Receptor 1 Gastric1, Glioma3, Liver4
10 CTNNA3 Catenin (Cadherin-Associated Protein), Alpha 3 Gastric1 (2), Glioma2, Lung-Brain1, Lung-Brain2
10 PFKP Phosphofructokinase, Platelet Glioma3, Lung5, Lung-Brain4
10 TACC2 Transforming, acidic coiled-coil containing protein 2 Gastric1, Lung2, Leukemia3, Liver4
10 DLG5 Discs, Large Homolog 5 (Drosophila) Glioma5, Liver1, Lung5 (2)
10 TET1 Tet Methylcytosine Dioxygenase 1 Glioma3, Lung5 (4), Lung-Brain2 (1 + 1)
11 NUMA1 Nuclear Mitotic Apparatus Protein 1 Glioma2, Glioma4, Lung2
11 PGAP2 Post-GPI attachment to proteins 2 Lung4, Lung5, Liver2
13 FREM2 FRAS1 Related Extracellular Matrix Protein 2 Liver1, Lung2, Lung-Brain2
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Table 2 Genes with LOH or GOH mutations in multiple cancer samplesa (Continued)
13 ZMYM2 Zinc Finger, MYM-Type 2 Gastric1, Liver1, Lung2
16 SLC38A8 Solute Carrier Family 38, Member 8 Glioma3, Glioma5, Lung-Brain2
16 RBFOX1 RNA Binding Protein, Fox-1 Homolog (C. Elegans) 1 Glioma3, Liver4, Lung5 (6)
17 SEPT9 Septin 9 Glioma1, Liver1, Lung5 (2)
17 CDK12 Cyclin-Dependent Kinase 12 Glioma5, Liver3, Lung5 (1 + 2)
17 DNAH9 Dynein, axonemal, heavy chain 9 Glioma3, Lung5 (2), Lung-Brain1, Lung-Brain4
17 GAS7 Growth Arrest-Specific 7 Gastric3 (2), Glioma2, Glioma3, Glioma4, Liver2,
Lung-Brain4
17 RPS6KB1 Ribosomal Protein S6 Kinase, 70 kDa, Polypeptide 1 Gastric1, Liver2 (3), Liver4, Lung5
17 WIPF2 WAS/WASL Interacting Protein Family, Member 2 Liver2, Lung4, Lung-Brain2
18 MBP Myelin Basic Protein Gastric1, Glioma4, Lung5
18 LAMA1 Laminin, Alpha 1 Glioma3, Liver4, Lung5
18 LDLRAD4 Low Density Lipoprotein Receptor Class A Domain
Containing 4
Gastric4, Glioma2, Glioma5, Lung5 (2), Lung-Brain4
18 GREB1L Growth Regulation By Estrogen In Breast Cancer-Like Liver4, Lung5, Lung-Brain2
19 GLTSCR1 Glioma Tumor Suppressor Candidate Region Gene 1 Glioma5, Lung-Brain4, Lung5
20 ZSWIM3 Zinc Finger, SWIM-Type Containing 3 Gastric1, Glioma3, Glioma5, Liver1
22 TRIOBP TRIO And F-Actin Binding Protein Glioma5, Lung5 (3), Lung-Brain2
C. Genes present in TSGene database with GOH occurrence in three or more cancer samplesb
Chrc Gene Description Samples with GOH sites
8 CSMD1f CUB and Sushi multiple domains 1 Gastric3 (2), Gastric4, Glioma3 (2), Lung5 (2)
9 PTPRDf Protein Tyrosine Phosphatase, Receptor Type, D Glioma1, Liver1, Lung5, Lung-Brain5
9 DAPK1 Death-Associated Protein Kinase 1 Glioma4, Liver1, Lung1
9 ROR2 Receptor Tyrosine Kinase-Like Orphan Receptor Gastric5, Glioma5, Lung5 (2)
11 ST5 Suppression of Tumorigenicity 5 Glioma3, Glioma4, Glioma5
12 CHFR Checkpoint with forkhead and ring finger domains, E3
ubiquitin protein ligase
Gastric1, Glioma5, Lung5 (3), Lung-Brain3
16 CDH1 f Cadherin 1, Type 1, E-Cadherin (Epithelial) Gastric2 (3), Lung5 (3), Lung-Brain4
22 CHEK2 f Checkpoint kinase 2 Glioma3, Lung2, Lung5
D. Additional genes present in NCG4.0 database with GOH occurrence in three or more cancer samplesb
Chrc Gene Description Samples with GOH sites
1 KAZN Kazrin, Periplakin Interacting Protein Gastric4, Glioma4, Lung5 (4)
1 FMN2 Formin 2 Lung5, Liver1, Lung-Brain1
1 NLRP3 NLR Family, Pyrin Domain Containing 3 Glioma3 (3), Liver1 (2), Lung5
4 FSTL5 Follistatin-Like 5 Liver4, Lung2, Lung5 (2)
5 PCDHGC5 Protocadherin Gamma Subfamily C, 5 Liver2, Lung2, Lung5 (2)
7 KMT2C Lysine (K)-Specific Methyltransferase 2C Gastric2, Gastric5 (2), Leukemia4, Liver2, Liver4
9 FNBP1 Formin Binding Protein 1 Glioma5, Lung5, Lung-Brain1
9 TRPM6 Transient Receptor Potential Cation Channel, Subfamily M,
Member 6
Glioma3, Liver4, Lung5
10 CTNNA3 Catenin (Cadherin-Associated Protein), Alpha 3 Glioma3, Liver1, Lung2, Lung5
10 PFKP Phosphofructokinase, Platelet Gastric1, Glioma1, Lung5
12 SP1 Sp1 Transcription Factor Glioma3, Glioma4, Lung4 (2)
12 KDM2B Lysine (K)-specific demethylase 2B Glioma5, Lung5, Lung-Brain4
12 ERC1 ELKS/RAB6-Interacting/CAST Family Member 1 Gastric1, Lung2, Lung5, Liver5
13 ATP11A ATPase, class VI, type 11A Glioma3, Liver1, Liver2
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Table 2 Genes with LOH or GOH mutations in multiple cancer samplesa (Continued)
16 CNOT1 CCR4-NOT Transcription Complex, Subunit 1 Glioma2, Glioma3, Lung5
16 SNX29 Sorting nexin 29 Gastric5, Lung5 (3), Liver1, Lung-Brain2
16 RBFOX1 RNA Binding Protein, Fox-1 Homolog (C. Elegans) 1 Gastric2, Glioma3 (4), Liver1 (2), Liver2, Lung4, Lung5 (3)
17 SEPT9 Septin 9 Liver1, Lung3, Lung5
17 RPS6KB1 Ribosomal Protein S6 Kinase, 70 kDa, Polypeptide 1 Gastric3, Glioma4, Lung-Brain3
17 TRIM37 Tripartite Motif Containing 37 Glioma1 (2), Glioma3, Glioma4
17 ITGAE Integrin, Alpha E (Antigen CD103, Human Mucosal
Lymphocyte Antigen 1; Alpha Polypeptide)
Glioma3, Glioma4 (2), Glioma5, Lung5 (2)
18 GREB1L Growth Regulation By Estrogen In Breast Cancer-Like Lung2, Lung4, Lung-Brain2 (2)
19 PTPRS Protein tyrosine phosphatase, receptor type, S Gastric1, Glioma5, Lung4
22 TUBA8 Tubulin, alpha 8 Gastric5, Glioma3, Lung5
E. Additional genes present in Ensemble database with extensive LOH occurrencesg
Gene Description Samples with LOH sitese
2 MTA3 Metastasis associated 1 family, member 3 [Source:HGNC
Symbol;Acc:23784]
Gastric1, Lung-Brain2, Lung3 (2), Liver2, Lung-Brain3
3 EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon,
82 kDa [Source:HGNC Symbol;Acc:3261]
Glioma3, Lung5 (8), Liver5, Leukemia1
4 SMIM14 Small integral membrane protein 14 [Source:HGNC
Symbol;Acc:27,321]
Liver2, Lung-Brain5, Glioma3, Leukemia5, Lung1 (2)
6 ATXN1 Ataxin 1 [Source:HGNC Symbol;Acc:10548] Glioma5, Lung4, Lung5, Liver1, Lung-Brain5
6 RP11-146I2.1 Not Applicable Glioma3, Lung3, Lung5, Liver2, Lung-Brain4
7 COL26A1 Collagen, type XXVI, alpha 1 [Source:HGNC
Symbol;Acc:18038]
Gastric1, Lung1, Lung2, Liver1, Lung-Brain1
7 TYW1B tRNA-yW synthesizing protein 1 homolog B (S. cerevisiae)
[Source:HGNC Symbol;Acc:33908]
Gastric1, Glioma3, Glioma5, Lung1, Lung5
8 LOXL2 Lysyl oxidase-like 2 [Source:HGNC Symbol;Acc:6666] Liver2 (2), Glioma3, Glioma4, Liver1, Liver3
8 RP11-124B13.1 Not Applicable Gastric1, Glioma1, Glioma3, Lung2, Liver2
9 DMRT1 Doublesex and mab-3 related transcription factor 1
[Source:HGNC Symbol;Acc:2934]
Glioma5, Gastric3, Lung5, Glioma1, Gastric1, Lung-Brain2
9 ODF2 Outer dense fiber of sperm tails 2 [Source:HGNC
Symbol;Acc:8114]
Lung-Brain2, Lung5 (2), Glioma5, Lung4, Lung-Brain4,
Liver4
10 CAMK1D Calcium/calmodulin-dependent protein kinase ID
[Source:HGNC Symbol;Acc:19341]
Lung5 (4), Liver5, Glioma5 (2), Leukemia4, Lung-Brain4,
Liver1 (1 + 1), Glioma3
10 FRMD4A FERM domain containing 4A [Source:HGNC
Symbol;Acc:25491]
Lung5 (2 + 8), Glioma5, Glioma3, Gastric1, Liver5
11 TMEM135 Transmembrane protein 135 [Source:HGNC
Symbol;Acc:26167]
Gastric1, Glioma3, Glioma4, Glioma5, Lung3
14 KLC1 Kinesin light chain 1 [Source:HGNC Symbol;Acc:6387] Liver5, Lung-Brain2, Gastric1, Glioma3, Liver2, Lung5
16 ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1
[Source:HGNC Symbol;Acc:51]
Lung5 (2 + 2), Lung1, Liver2, Lung-Brain2, Lung-Brain1
16 C16orf45 Chromosome 16 open reading frame 45 [Source:HGNC
Symbol;Acc:19213]
Gastric1, Glioma3, Lung2, Lung5, Lung-Brain5
17 NMT1 N-myristoyltransferase 1 [Source:HGNC Symbol;Acc:7857] Glioma5, Liver4, Lung5 (2), Gastric1 (2), Glioma3,
17 PITPNC1 Phosphatidylinositol transfer protein, cytoplasmic 1
[Source:HGNC Symbol;Acc:21045]
Gastric1, Gastric4, Glioma3, Glioma5, Lung2
17 RAP1GAP2 RAP1 GTPase activating protein 2 [Source:HGNC
Symbol;Acc:29176]
Liver2 (2), Glioma5 (2), Lung-Brain2 (2 + 1), Gastric5,
Gastric1, Lung4, Lung5
17 RBFOX3 RNA binding protein, fox-1 homolog (C. elegans) 3
[Source:HGNC Symbol;Acc:27097]
Glioma3, Glioma5, Liver3, Lung-Brain4 (1 + 3), Lung-Brain5
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Table 2 Genes with LOH or GOH mutations in multiple cancer samplesa (Continued)
18 DLGAP1 Discs, large (Drosophila) homolog-associated protein 1
[Source:HGNC Symbol;Acc:2905]
Lung-Brain2, Lung5 (2 + 1), Gastric4, Gastric1, Lung-Brain2,
Glioma3
19 INSR Insulin receptor [Source:HGNC Symbol;Acc:6091] Liver3, Liver4, Lung2, Lung5 (1 + 1), Gastric1 (2)
19 SIPA1L3 Signal-induced proliferation-associated 1 like 3
[Source:HGNC Symbol;Acc:23801]
Glioma3, Lung-Brain2, Liver2, Lung5, Glioma3, Lung5
19 TDRD12 Tudor domain containing 12 [Source:HGNC
Symbol;Acc:25044]
Lung-Brain1, Glioma5, Lung1, Glioma5, Glioma2, Liver2
19 GNG7 Guanine nucleotide binding protein (G protein), gamma
7 [Source:HGNC Symbol;Acc:4410]
Lung5 (1 + 7), Lung-Brain4 (3)
22 SYN3 Synapsin III [Source:HGNC Symbol;Acc:11496] Lung3, Lung5, Lung-Brain4, Glioma3 (1 + 2), Glioma5
F. Additional genes present in Ensemble database with extensive GOH occurrencesg
Chrc Gene Description Samples with GOH sitese
1 RPRD2 Regulation of nuclear pre-mRNA domain containing 2
[Source:HGNC Symbol;Acc:29039]
Gastric2, Glioma3, Glioma4, Glioma5 (2), Liver1, Lung4,
Lung5
1 CLSTN1 Calsyntenin 1 [Source:HGNC Symbol;Acc:17447] Gastric5, Lung2, Lung5, Lung-Brain2, Lung-Brain4
1 KIF26B Kinesin family member 26B [Source:HGNC
Symbol;Acc:25484]
Liver3, Glioma3, Glioma5 (2), Lung5 (3), Gastric1
1 GON4L Gon-4-like (C. elegans) [Source:HGNC Symbol;Acc:25973] Lung2 (2), Lung5 (2), Glioma4 (2), Lung-Brain1, Gastric4
1 NMNAT2 Calsyntenin 1 [Source:HGNC Symbol;Acc:17447] Glioma5, Lung1, Lung5, Liver1, Lung-Brain1
2 FAM178B Family with sequence similarity 178, member B
[Source:HGNC Symbol;Acc:28036]
Gastric5, Glioma3, Liver3, Liver5, Lung3
2 MTA3 Metastasis associated 1 family, member 3 [Source:HGNC
Symbol;Acc:23784]
Glioma1, Glioma2, Glioma4, Liver1, Lung-Brain3
3 EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon,
82 kDa [Source:HGNC Symbol;Acc:3261]
Gastric3, Glioma5 (3), Lung5, Lung-Brain2, Lung-Brain4
4 AFAP1 Actin filament associated protein 1 [Source:HGNC
Symbol;Acc:24017]
Glioma3 (2), Liver1, Lung5 (6), Leukemia4, Liver4, Glioma5
5 PDZD2 PDZ domain containing 2 [Source:HGNC Symbol;Acc:18486] Lung2, Lung5 (4), Glioma1, Gastric2, Glioma3 (2)
5 PCDHGA1 Protocadherin gamma subfamily A, 1 [Source:HGNC
Symbol;Acc:8696]
Glioma3, Glioma5, Liver2, Lung2, Lung5 (2)
7 CALN1 Calneuron 1 [Source:HGNC Symbol;Acc:13248] Glioma3, Glioma3, Lung2 (5), Lung4, Lung5 (2)
7 KMT2C Protocadherin gamma subfamily A, 1 [Source:HGNC
Symbol;Acc:8696]
Gastric2, Gastric5 (2), Liver2, Liver4, Leukemia4
7 TYW1 tRNA-yW synthesizing protein 1 homolog (S. cerevisiae)
[Source:HGNC Symbol;Acc:25598]
Glioma3, Glioma5 (3), Liver1, Lung-Brain1 (5)
8 PSD3 Pleckstrin and Sec7 domain containing 3 [Source:HGNC
Symbol;Acc:19093]
Lung3, Lung5 (9)
10 CAMK1D Calcium/calmodulin-dependent protein kinase ID
[Source:HGNC Symbol;Acc:19341]
Glioma3, Liver1, Lung3, Lung4 (5), Lung5 (5), Glioma4
11 SHANK2 SH3 and multiple ankyrin repeat domains 2 [Source:HGNC
Symbol;Acc:14295]
Glioma3, Lung3, Lung5, Liver1, Liver5
12 MPHOSPH9 M-phase phosphoprotein 9 [Source:HGNC
Symbol;Acc:7215]
Leukemia3, Lung-Brain5, Lung2, Lung4 (2), Lung5, Glioma4
17 STX8 Syntaxin 8 [Source:HGNC Symbol;Acc:11443] Glioma3, Glioma4 (2), Lung2, Lung4 (2), Leukemia2
17 USP43 SH3 and multiple ankyrin repeat domains 2 [Source:HGNC
Symbol;Acc:14295]
Liver1, Lung2, Lung5, Glioma5, Lung-Brain4
19 INSR Insulin receptor [Source:HGNC Symbol;Acc:6091] Liver4, Glioma3 (2), Glioma4 (2), Lung-Brain3, Lung5 (3)
19 CTC-490E21.12 Not Applicable Gastric2, Gastric3, Glioma4, Glioma5, Lung1
19 CTC-525D6.1 Not Applicable Gastric2 (4), Lung5 (8)
19 SAE1 SUMO1 activating enzyme subunit 1 [Source:HGNC
Symbol;Acc:30660]
Glioma3, Lung2, Lung4, Lung5, Liver1
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file 10: Table S8) interact with high likelihood genes from
Table 2 that displayed multiple LOH and/or GOH muta-
tions in the four solid tumor types (shown as color-coded
sectors). Notably the genes CTNNA3, DLGAP1, CDH1,
CHEK2, SAE1, SP1, RPS6KB1, AXIN1 and DNAJA3 were
included in the high-likelihood genes in Table 2 as well as
the CIPHER-identified high-risk genes. The network in
Fig. 4a illustrates the utility of the identified multi-
LOH/GOH genes in combination with CIPHER for
analyzing potential protein-protein interactions in onco-
genic networks.
Besides the multiple LOH- or GOH-bearing cancer-
related genes detected, a host of other genes from the
Ensembl database that were unlisted in either TSGene
or NCG4.0 also underwent LOH and GOH mutations
(Additional file 9: Tables S7E-F), and those unlisted
genes that displayed highest occurrences of LOH or GOH,
or in the largest numbers of cancer samples, are shown in
Tables 2E-F, e.g. FRMD4A with fourteen LOHs, CAMK1D
with 12 LOHs and 14 GOHs, AFAP1 with twelve GOHs,
and LARGE with eleven GOHs. Based on the multiplicity
of LOH and/or GOH mutations displayed by these genes
in the various cancer samples, they would represent
potential cancer-related genes that merit further inves-
tigation: eight of these genes, viz. DLGAP1, SHANK2,
EIF2B5, SAE1, INSR, ATXN1 and RBFOX1 are in-
cluded in Fig. 4a along with 20 tumor-suppressor and
cancer related genes from Table 2A-D. These findings
underline the usefulness of comprehensive LOH and
GOH tracking in multiple cancers for uncovering po-
tential cancer-related genes.
Discussion
On account of the complexity of cancer cells, genomic
studies provide an excellent approach to find surprises
[24]. In the present study, a characterization of the land-
scape of cancer LOHs revealed the surprisingly massive
rates of LOH formation in various cancers, far exceeding
the rates of GOH-M formation, and these cancer LOHs
displayed a number of special properties.
Table 2 Genes with LOH or GOH mutations in multiple cancer samplesa (Continued)
20 ATP9A ATPase, class II, type 9A [Source:HGNC Symbol;Acc:13540] Liver1 (3), Glioma4, Gastric3, Lung4, Lung5 (2)
22 LARGE Like-glycosyltransferase [Source:HGNC Symbol;Acc:6511] Liver1 (2), Lung1, Lung2, Leukemia5 (2), Glioma5 (3),
Gastric5 (2)
22 SGSM1 Lysine (K)-specific methyltransferase 2C [Source:HGNC
Symbol;Acc:13726]
Gastric2, Glioma3, Leukemia5, Lung-Brain2 (2), Lung-Brain3
aSee Additional file 9: Table S7A-F for complete lists of genes with LOH or GOH occurrence
bTSGene: Tumor Suppressor Gene Database, containing 860 genes; NCG4.0: Network of Cancer Genes, containing 2000 genes
c Chromosome on which the indicated gene is located
dLOH-containing genes present in both TSGene and NCG4.0 databases are only listed in Table 2A but not Table 2B
eThe bold-fonted LOH occurrences represent Mm-to-mm conversions, and the non-bold-fonted LOH occurrences represent Mm-to-MM conversions. Where a
sample contained more than one LOH, the number of LOHs is indicated inside parenthesis, either in bold font for LOHs yielding mm genotypes, or in non-bold
font for LOHs yielding MM genotypes
fGOH-containing genes present in both TSGene and NCG4.0 databases are only listed in Table 2C but not Table 2D
gThe list includes LOH- or GOH-bearing genes in Ensemble database (GRCh37.p13), which contains 57,736 genes, that are not in TSGene or NCG4.0
Fig. 4 Mutations in solid tumors. a CIPHER analysis. Genes from Table 2 with multiple LOH or GOH mutations in gliomas, lung cancers, liver
cancers and gastric cancers are marked in blue, yellow, green and red respectively, or multi-colored where such mutations were detected in
more than one of these types of cancers. Genes identified by CIPHER to be high-risk for this group of cancers are enclosed by purple circle.
b Comparison with leukemias in RLOH rates. The sample average RLOH rates of the twenty-five solid tumors and five leukemias are given in Table 1
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Features of cancer copy-neutral LOHs
Unequal incidences in solid tumors and leukemias
In Table 1, the average leukemia RLOH of 0.61 % Mm resi-
dues was significantly lower than the average solid tumor
RLOH of 10.2 % Mm residues with p = 0.0003 (Fig. 4b), in
accord with previous reports of lower mutation rates in
leukemias compared to solid tumors [25, 26]. Further-
more, insofar that the leukemia and solid tumor samples
were analyzed using the same procedures, the leukemia
RLOH of 0.61 % Mm residues suggests that the maximum
technical error in the estimation of both leukemia and
solid tumor RLOH incurred by false-positive calling of
LOHs would not exceed 0.61 % Mm residues, amounting
to only 0.61/10.2, or 6 % error, for the solid tumors. At the
other extreme, the exact causes for the extraordinary
>20 % RLOH rates of Gastric 1, Glioma 3, Glioma 5, Liver
1, and Lung 5 were undetermined; these cancers could be
entering a terminal state of cellular disarray, and contribu-
tion from treatment modality-induced chromosomal in-
stability also could not be ruled out.
Interstitial distribution
Among different chromosomes, dense LOHs were present
over large portions of chr 19, chr 17, chr 16p, chr 22q, and
parts of chr 1p, chr 6p, chr 9q and chr 11q, but were rela-
tively sparse in chr 4, chr 8, chr 13, chr 18 and chr 21
(Fig. 2a). Some but not all of the dense LOH regions over-
lapped with the locations of known common or rare fragile
sites. Association of LOHs with CNVs was evident in some
instances, notably in Glioma 1, but such CNV-associated
LOHs represented only a minor fraction of the LOHs ob-
served (Fig. 1, Additional file 7: Table S4).
The mainly interstitial character of the cancer LOHs
was evident from the well-spaced LOH occurrences in
the sparse LOH regions of Fig. 2a and most regions in
Fig. 2b and c, as well as the distribution of LOH frag-
ment lengths showing a substantial fraction of fragments
that were ≤ 1 Mb in size (Fig. 5; Additional file 11: Table S9).
It was also evident in the LOH-dense regions in Fig. 2a,
where the crowded interspersion of LOHs and GOHs was
incompatible with the dense LOHs being the result of
any extended stretches of CN-losses. The interstitial na-
ture of the major fraction of copy-neutral LOHs observed
supports gene conversion being an important mechanism
in the production of cancer LOHs.
Reduced LOHs on X-chromosomes
RLOH, the rate of LOH occurrence expressed as the
percentile conversion of Mm residues analyzed, varied
between different chromosomes (Fig. 6a). Among the auto-
somal chromosomes, this rate ranged from 5.5 % in chr 20
to 8.4 % in chr 13 (Additional file 4: Table S3.31). However,
it was only 3.6 % in the X chromosomes in the female
samples, which suggests that the inactive Barr-body
configuration of one of the X-chromosomes [27] might
constrain its participation in interhomolog recombination
and LOH production relative to other chromosomes.
Interestingly, the four chromosomes exhibiting the
highest levels of LOH/Mm, viz. chr 13, chr 22, chr 18
and chr 14, are known for their propensity to chromo-
somal instability as indicated by the frequency of trisomy
[28, 29]. Also, the ~10−5 frequency of LOH occurrence
on the various chromosomes expressed on a per bp basis
(Fig. 6b) was similar to the 10−6 to 5 × 10−5 per bp fre-
quencies displayed by TCGA ovarian cystadenoma and
glioblastoma genomes [6].
Preferences for reference alleles and transitional changes
The partition of Mm genotypes between the MM and
mm outcomes of LOH was characterized by a preference
for MM over mm genotypes, with transitional LOHs
being more prominent than transversional ones in the
process (Additional file 12: Figure S2). Plausibly the M-
alleles in the human genome were selected in the course
of primate and human evolution to result in the adoption
of MM genotypes at >99.9 % of the residues in the human
genome. This bias in favor of the MM over Mm and mm
genotypes suggests that, although the presence of m-
alleles in the genome confers beneficial sequence diversity
and gene-dosage modulation, functional advantages gen-
erally accrue to the M-alleles over m-alleles at most of
the base positions in the genome. Accordingly, although
key LOHs introducing mm-genotypes into tumor sup-
pressor genes could facilitate oncogenesis [1], excessive
accumulation of mm-genotypes might be detrimental to
the cancer cells themselves, leading to selection against
them and M-allele preference.
The taller column heights of transitional over transver-
sional LOHs giving rise to MM-genotypes in Fig. 3a, b,
and to a lesser extent in Fig. 3c, was in accord with the
greater frequencies of transitional compared to transver-
sional mutations in organisms.
Mode of double strand break repair in cancers
Since random point mutations would yield similar rates of
mutation of Mm residues to yield LOHs and MM residues
to yield GOHs, the vastly higher RLOH than RGOH-M values
in Table 1 rule out point mutations as an important mech-
anism for the generation of cancer LOHs. This together
with the limited role of CNV focuses attention on repair
of double strand breaks (DSB) as a major source of
cancer LOHs. In eukaryotic cells, DSBs are repaired by
a spectrum of mechanisms through non-homologous end-
joining, and homologous recombinations (HR) that in-
clude crossover pathways, break-induced replication, and
synthesis-dependent strand-annealing employing a repair
template supplied by sister chromatid in inter-sister chro-
matid recombination (ISR), a homologous chromosome in
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interhomolog recombination (IHR), or some ectopic se-
quence to bring about gene conversion [30].
Break-induced replication would be inconsistent with
the largely interstitial character of the LOHs, and
deletions of base residues at Mm sites due to non-
homologous end-joining would not be called as SNVs
(either LOHs or GOHs) in variant analysis (see Methods).
In contrast, the HR process is known to produce relatively
short patches of new DNA [31], in accord with the intersti-
tial character of the cancer LOHs. Because ISR enhances
both RMM and RLOH comparably whereas IHR enhances
RLOH far in excess of RMM, the finding of RLOH > > RGOH-
M with the different types of cancers strongly favored IHR
over ISR as the underlying mechanism for the massive can-
cer LOHs. This conclusion was supported by the linear
correlations between the levels of LOH, GOH-M and
GOH-m, where GOH-M denotes GOHs arising from
homozygous MM residues, and GOH-m denotes GOHs
arising from homozygous mm residues (Fig. 7). That the
occurrence of GOH mutations in MM and mm tagged
along in correlation with the occurrence of LOH muta-
tions was to be expected with IHR, which would cause
not only the Mm residues involved to undergo LOH
mutation due to the use of the allelic template for DSB
repair, but also significant mutations of the Mm, MM
and mm residues involved owing to the highly error-
prone nature of the DNA polymerase employed for invad-
ing strand elongation in the course of IHR, increasing the
mutation rate by up to 1400-fold [32]. That RGOH-m was
also much greater than RGOH-M would be consistent with
Fig. 5 LOH fragment lengths. a Length distribution of total LOHs. b Expanded distribution of ≤ 1 Mb fraction of LOHs (green column in Part A).
Distributions are based on total LOHs observed in the thirty tumors in Table 1 analyzed using AluScan. Individual fragment lengths are given in
Additional file 11: Table S9
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the presence of extensive selection against mm-genotypes
during cancer cell evolution, as suggested by the prefer-
ence for M-alleles amongst the cancer LOHs.
The choice between ISR and IHR for DSB repair de-
pends on a wide array of regulatory factors [33]. IHR
prevails in meiotic cells. In mitotic cells, ISR prevails
over IHR on account of the close positioning of sister
chromatids secured by cohesin [34–36], but IHR can be
increased upon induction of a chromosomal DSB by two
to three orders of magnitude up to 1 % of the target sites
to yield short tract nonreciprocal gene conversions [37].
Cellular systems are also known to undergo enhanced
LOH production under special circumstances. In a Bloom
mouse model, Blm-deficient ES cells exhibited elevated
mitotic recombination rates with an 18-fold increase in
somatic LOH [38]. In aging diploid mother yeast cells, re-
combination rates could increase to 200-fold the rate in
young cells to result in an age-induced switch to a
hyper-recombination state [39]. Thus the degenerative
states in ageing yeast cells and the various types of
tumors analyzed in Table 1 shared the common attribute
of hyper-recombination. Interestingly, copy-neutral LOHs
Fig. 6 Relative abundance of LOH on different chromosomes. Estimates were based on the number of LOHs detected on each of the twenty-two
autosomal chromosomes in the thirty cancer samples analyzed using AluScan in Table 1, and on the X chromosome in only the nine female cancer
patients. a LOH per Mm site analyzed on each chromosome. b LOH per bp analyzed on each chromosome
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in ovarian cancer were found to be more frequent in older
patients, suggesting that the effects of cancer and ageing
could be additive in this regard [40].
The rate of DSB occurrence in cells has been esti-
mated at about 50 DSBs per cell per cell cycle [41] or
ten per day [42], and it is increased by both exogenous
agents such as chemicals, ultraviolet and ionizing radi-
ation, and endogenous events such as arrested replica-
tion forks, nucleases and reactive oxygen species from
cellular metabolism [30, 43]. In the event that both lead-
ing and lagging strands of DNA are synthesized by
discontinuous synthesis in human cells as has been sug-
gested for Escherichia coli [44, 45], DNA synthesis itself
can be a significant source of DSBs [33]. Evidence for
oncogene-induced DSBs has been provided by using the
presence of p53 binding protein 1 (53BP1) nuclear foci
as indicator of DSBs, whereby 10–20 foci per cell could
be detected in cancer cell lines but not in proliferating
normal cells [46].
Defective DNA-damage response
To cope with the continuous threat of DSBs, eukaryotic
cells possess the capacity to mount a DNA-damage re-
sponse (DDR) that arrests cell-cycle progression at the
G1-S, intra-S and G2-M checkpoints to increase the time
available for DNA repair; if the DNA damage cannot be
removed, chronic DDR triggers cell death by apoptosis
or cellular senescense [47–49]. Analysis of the relation-
ship between DDR and oncogenesis has brought import-
ant insight into how oncogene activation-induced DNA
hyper-replication could lead to S-phase DNA damage,
onset of DDR and abrogation of cell cycle checkpoints,
leading to a circumvention of the apoptosis and senes-
cence pathways normally elicited by DDR, and hence
oncogenesis [46, 50–52]. Notably, this chain of events,
by diminishing or nullifying the action of the cell cycle
checkpoints, not only would increase the influx of DSB-
bearing DNA into the S-phase during the pre-oncogenesis
phase to induce oncogenesis, but also may be expected to
continue in the post-oncogenesis phase.
While usage of IHR for DSB repair is suppressed in
favor of ISR in mitotic cells, the situation is radically
altered upon oncogenesis and relaxation of checkpoints
to enable the entry of DSB-bearing DNAs into S-phase.
Under these circumstances, when a DSB-bearing chro-
matid replicates to yield a sister chromatid, the two sis-
ter chromatids will be unable to provide a useful repair
template to one another. Instead, either a homologous
chromosome or a homologous ectopic sequence will have
to supply the requisite repair template [53]. Given the
reliable presence of the homologous chromosome as tem-
plate compared to the haphazard availability of a homolo-
gous ectopic sequence, DSB repair by IHR will prevail
giving rise to hyper-accumulation of LOH mutations in
the cancer cells. Although DSB repair by HR in general
can be a source of mutations arising from error-prone
polymerases or replication forks [32, 54, 55], in the pres-
ence of intact cell cycle checkpoints ISR will be strongly
preferred over IHR for DSB repair during S-G2, such that
the error-prone polymerases would bring about compar-
able RGOH-M and RLOH rates instead of the vastly higher
RLOH than RGOH-M rates found in cancer samples. There-
fore only impaired cell cycle checkpoints arising from a
defective DDR can lead to the hugely greater RLOH than
RGOH-M displayed by different types of cancer cells.
Fig. 7 Linear correlations between three different types of mutations
in cancer genomes. a Correlation between LOH and GOH-M,
correlation coefficient =0.984. b Correlation between LOH and GOH-m,
correlation coefficient = 0.920. c Correlation between GOH-m and
GOH-M, correlation coefficient = 0.923. Each point represents the
total number of each type of mutations detected on one of
twenty-two autosomal chromosomes in all thirty cancer samples
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Conclusions
The question has been posed regarding how might the
requisite genetic changes, estimated to be about six mu-
tations, be acquired to initiate oncogenesis, and whether
mutator phenotypes participate in the process [56]. This
question is important not only to oncogenesis, but also
to the post-oncogenesis phase with respect to the muta-
tions needed to implement the manifold hallmarks of
the neoplastic state, i.e. sustaining proliferative signaling,
evading growth suppressors, resisting cell death, enab-
ling replicative immortality, inducing angiogenesis, and
activating invasion and metastasis [57], and complex
metabolic reprogramming to support rapid growth even
under conditions of fluctuating oxygen tension through
enhanced glucose uptake, aerobic glycolysis, decreased
conversion of pyruvate to acetyl-CoA etc. [58]. Thus
solid tumors compared to leukemias are confronted with
irregular vascularization and more fluctuations in oxy-
gen tension and nutrient supplies, which might contrib-
ute to the higher percentile LOH and GOH occurrences
displayed by solid tumors compared to leukemias (Fig. 4b).
Overall, the intimate relationship between defective DDR
and cancer is clearly underlined by the numerous human
genetic diseases that are associated with both DDR defects
and predisposition to cancers including xeroderma pig-
mentosum, familial breast cancer, Bloom syndrome, MYH-
associated polyposis, hereditary nonpolyposis colorectal
cancer, etc. [59].
Accordingly, in the pre-oncogenesis phase, the weaken-
ing of cell cycle checkpoints caused by oncogene-induced
DDR alterations can usher in mutations to initiate onco-
genesis [46, 50–52]. In the post-oncogenesis phase, a de-
fective DDR allows the continued accumulation of LOHs
and GOHs, which can be self-amplifying insofar that some
of the accumulated mutations can further alter DDR, to
result in the wide landscape of mutations including LOHs,
GOHs, CNVs, indels and chromosomal instabilities that
characterize cancers, thus meeting fully the mutations
needed for post-oncogenesis alterations which may be ex-
pected to outnumber those required for oncogenesis.
Table 2 illustrates some of the LOH and GOH mutations
in tumor suppressor and other cancer related genes poten-
tially arising from interhomolog recombination enabled by
a defective DDR that could be utilized by various cancers.
In conclusion, analysis of cancer LOHs and GOHs in
the present study has revealed evidence for the occur-
rence of LOHs and tag-along GOHs in cancers brought
about by repair of DSBs through interhomolog recombin-
ation under conditions of relaxed cell cycle checkpoints
due to a defective DDR. On this basis, cancer may be
regarded foremost as a disease of the DNA-damage re-
sponse, where the mutator phenotype arising from DDR
derangement provides a unified mechanism for generating
interhomolog recombination-induced mutations (Fig. 8)
to drive the initiation, development and aggressive-
ness of the neoplastic state from its oncogenic begin-
ning to its terminal stages of unconstrained growth
and proliferation.
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